Roche Sees Access Programs As Key To Growth In China, Brazil: Emerging Market Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
With biosimilars on the horizon, the Swiss pharma cites Herceptin and MabThera as key growth drivers in emerging markets.
You may also be interested in...
Driven By Herceptin Franchise, Roche Hopes Rituxan Will Follow Suit
The Swiss pharma reported a positive start to the year with its first quarter earnings on April 11, underscoring the strength of its oncology products as it continues to work on lifecycle management.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.